glp 1 with medicaid Coverage of and Spending on GLP-1s McKee's proposed FY2027 budget drops

The 2nd GLP-1-Based Therapeutics Summit returns to tackle the challenges in best-in-class GLP-1 development and indication expansion with new clinical data, new preclinical data, and 18+ expert speakers including Eli Lily, Regeneron, Roche, Novo Nordisk, Fractyl Health and more at the forefront of the field

Learn more about this research:

With GLP1 therapeutics entering their second wave of innovation, this is a pivotal moment for teams pushing boundaries in metabolic and neuroendocrine drug development

This temporary allowance enabled pharmacies to meet surging demand, particularly among patients seeking anti-obesity medications who now represent approximately 83% of the compounded GLP-1 market

To minimize selection bias, we employed 1:1 propensity score matching to account for demographic factors such as age, sex, race, and comorbidities